Versartis Priced, Nasdaq: VSAR
Biotech developing long-acting treatments for growth hormone deficiency.
Industry: Health Care
First Day Return: +49.4%
VSAR
Biotech developing long-acting treatments for growth hormone deficiency.
| IPO Data | |
|---|---|
| IPO Date | 03/20/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $126 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Redwood City, CA, United States |
| Founded | 2008 |
| Employees at IPO | 14 |
| Website www.versartis.com | |
Versartis (VSAR) Performance
